1. Search Result
Search Result
Results for "


" in MCE Product Catalog:


Inhibitors & Agonists




Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-90006


    Nucleoside Antimetabolite/Analog HIV Apoptosis Endogenous Metabolite Cancer
    5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer. 5-Fluorouracil also inhibits HIV.
  • HY-14769

    5,10-Methylenetetrafolate; ANX-510 free acid

    Endogenous Metabolite Cancer
    Folitixorin (5,10-methylenetetrahydrofolate) is a cofactor and an analog of leucovorin. Folitixorin is a promising agent for modulation of 5-FU cytotoxicity in adjuvant cancer research.
  • HY-106406

    BAU; 5-Benzylacyclouridine

    Others Cancer
    Benzylacyclouridine (BAU) is a potent and specific inhibitor of uridine phosphorylase, the first enzyme in the catabolism of uridine. Benzylacyclouridine can modulate the cytotoxic side effects of 5-fluorouracil (5-FU) and its derivatives.
  • HY-B0016

    DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.
  • HY-17400

    FT 207; NSC 148958

    Nucleoside Antimetabolite/Analog Cancer
    Tegafur (FT 207; NSC 148958) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers; is a component of tegafur-uracil.
  • HY-W010450

    Endogenous Metabolite Cancer Metabolic Disease
    Thymine is one of the four nucleobases in the nucleic acid of DNA and can be a target for actions of 5-fluorouracil (5-FU) in cancer treatment, with a Km of 2.3 μM.
  • HY-B0016S

    DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Capecitabine-d11 is the deuterium labeled Capecitabine. Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.
  • HY-17511
    Potassium oxonate

    Potassium azaorotate; Potassium otastat

    Others Metabolic Disease
    Potassium oxonate is an inhibitor of uricase, inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate catalyzed by pyrimidine phosphoribosyl-transferase in a different manner from allopurinol in cell-free extracts and intact cells in vitro.
  • HY-10533

    5-Ethynyluracil; GW776C85

    Others Cancer
    Eniluracil (5-Ethynyluracil), a uracil analogue and a mechanism-based irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD), increases the oral bioavailability of 5-fluorouracil (5-FU) to 100%, facilitating uniform absorption and predictable toxicity.
  • HY-139065

    Others Cancer
    AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research.
  • HY-14905
    Uridine triacetate

    Tri-O-acetyl uridine

    Others Neurological Disease
    Uridine triacetate (Tri-O-acetyl uridine) is an orally active prodrug of Uridine. Uridine triacetate (Tri-O-acetyl uridine) is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate (Tri-O-acetyl uridine) is uesd for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Uridine triacetate (Tri-O-acetyl uridine) delivers high concentrations of uridine, which competes with toxic 5-FU metabolites.
  • HY-N0669

    Others Cancer
    Stevioside is a natural sweetener extracted from leaves of Stevia rebaudiana, with anticancer activity.
  • HY-109115
    Fosifloxuridine nafalbenamide


    Thymidylate Synthase Cancer
    Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunotherapy.